Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 2 |
2024 | 2 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Page 1
Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa.
NEJM Evid. 2024 Mar;3(3):EVIDoa2300155. doi: 10.1056/EVIDoa2300155. Epub 2024 Feb 9.
NEJM Evid. 2024.
PMID: 38335032
Clinical Trial.
Kinase Inhibitors for Hidradenitis SuppurativaThree kinase inhibitor immunomodulators (daily oral brepocitinib, zimlovisertib, and ropsacitinib) were evaluated in this randomized, placebo-controlled trial of 194 patients with hidradenitis suppurativa. ...
Kinase Inhibitors for Hidradenitis SuppurativaThree kinase inhibitor immunomodulators (daily oral brepocitinib, zimlovisertib, and ro …
A Phase 1 Study to Assess Mass Balance and Absolute Bioavailability of Zimlovisertib in Healthy Male Participants Using a (14) C-Microtracer Approach.
Singh RSP, Dowty ME, Salganik M, Brodfuehrer JI, Walker GS, Sharma R, Beebe JS, Danto SI.
Singh RSP, et al.
Clin Pharmacol Drug Dev. 2022 Jul;11(7):815-825. doi: 10.1002/cpdd.1109. Epub 2022 May 4.
Clin Pharmacol Drug Dev. 2022.
PMID: 35506501
Free PMC article.
Clinical Trial.
All six participants received 300 mg (14) C-zimlovisertib with lower radioactivity per mass unit orally in Period A, then unlabeled zimlovisertib 300 mg orally and (14) C-zimlovisertib 135 mug intravenously (IV) in Period B. Study objectives included extent a …
All six participants received 300 mg (14) C-zimlovisertib with lower radioactivity per mass unit orally in Period A, then unlabeled …
Item in Clipboard
Binding Energy Partition of Promising IRAK-4 Inhibitor (Zimlovisertib) for the Treatment of COVID-19 Pneumonia.
Zapata-Acevedo CA, Guevara-Vela JM, Popelier PLA, Rocha-Rinza T.
Zapata-Acevedo CA, et al.
Chemphyschem. 2022 Dec 16;23(24):e202200455. doi: 10.1002/cphc.202200455. Epub 2022 Oct 18.
Chemphyschem. 2022.
PMID: 36044560
Free PMC article.
We investigated the interactions of different fragments of ligands and Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4) throughout the FBDD design of Zimlovisertib, a promising anti-inflammatory, currently in trials to be used for the treatment of COVID-19 pneumonia. .. …
We investigated the interactions of different fragments of ligands and Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4) throughout the FB …
Item in Clipboard
In Retrospect: Root-Cause Analysis of Structure-Activity Relationships in IRAK4 Inhibitor Zimlovisertib (PF-06650833).
Wright SW, Farley KA, Han S, Knafels JD, Lee KL.
Wright SW, et al.
ACS Med Chem Lett. 2024 Mar 21;15(4):540-545. doi: 10.1021/acsmedchemlett.4c00036. eCollection 2024 Apr 11.
ACS Med Chem Lett. 2024.
PMID: 38628800
In this paper, we disclose insights on the root causes of three structure-activity relationship (SAR) observations encountered in the discovery of the IRAK4 inhibitor Zimlovisertib (PF-06650833). The first is a nonlinear potency SAR encountered with the isoquinoline ether …
In this paper, we disclose insights on the root causes of three structure-activity relationship (SAR) observations encountered in the discov …
Item in Clipboard
Cite
Cite